1. International Conference on Harmonisation (ICH). Guideline on Pharmacovigilance planning (E2E). https://database.ich.org/sites/default/files/E2E_Guideline.pdf. Accessed 18 Nov 2020.
2. Council for International Organizations of Medical Sciences (CIOMS). Management of Safety Information from Clinical Trials: Report of CIOMS Working Group VI. 2005. https://cioms.ch/wp-content/uploads/2017/01/Mgment_Safety_Info.pdf. Accessed 18 Nov 2020.
3. Tsinitis P, La Mache E. CIOMS and ICH initiatives in pharmacovigilance and risk management. Drug Saf. 2004;27(8):509–17.
4. European Parliament and Council. European Parliament Directive 2004/27/EC of The European Parliament and of the Council of 31 March 2004, amending Directive 2001/83/EC on the Community Code relating to medicinal products for human use. 2020. http://ec.europa.eu/health/files/eudralex/vol-1/dir_2004_27/dir_2004_27_en.pdf. Accessed 18 Nov 2020.
5. US Food and Drug Administration. Guidance for Industry Development and Use of Risk Minimization Action Plans. 2005. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/development-and-use-risk-minimization-action-plans. Accessed 18 Nov 2020.